Accelerator Directory / Institute Of Cancer Research: Royal Cancer Hospital (the)
We are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy. Together with our hospital partner The Royal Marsden NHS Foundation Trust, we are rated in the top four centres for cancer research and treatment worldwide.
As well as being as world-class research institute, the ICR is a higher education institution and a college of the University of London. We came top in the league table of university research quality compiled from the Research Excellence Framework (REF 2014).
The ICR has charitable status and relies on support from partner organisations, charities, donors and the general public.
The ICR is led by Chief Executive, Professor Paul Workman — an expert in cancer drug discovery.
The majority of ICR employees are directly engaged in research, but there are also important roles in scientific facilities, academic services, IT, fundraising, communication, human resources, and within our Enterprise unit, which negotiates collaborations between ICR scientists and industry.
The Enterprise Unit acts as the technology and knowledge transfer hub for The Institute of Cancer Research, providing the experience and expertise to put in place a wide range of agreements between our scientists and industry.
Although it is not our primary objective, the ICR has been extremely successful in getting a financial return from the commercial exploitation of its research. This income is largely ploughed back into scientific research at the ICR.
We currently have a number of partnering and licensing opportunities in therapeutics, targets, diagnostic biomarkers, devices, and platform or software applications."
- 4573 Biotechnology
- Company Number
- Private Limited by Guarantee/No Share Capital
- Company Age
- 64 years
- June 4, 1954
- Nature of Business
- 72190 - Other research and experimental development on natural sciences and engineering
- Year End
- July 31
- Accounts Due
- April 30, 2020
- Latest Accounts
- July 31, 2018
MARKET: M&A to ScaleUp
MARKET: Legaltech to the Crick
MARKET: Green power to Nanobots
COMPANIES: Ede & Ravenscroft to MRC
MARKET: Biotech Clusters to Ransomware
MARKET: Accelerators to Big Data
the GRID: mapping the growth company marketplace
MARKET: Foodtech to Smart Cities
MARKET: Circular Economy to Industrial Internet
COMPANIES: Oxford Sciences Innovation to Wimbledon
UK business delegation to China
MARKET: Bad Advice to UK Disruptors
COMPANIES: Metrasens to Otaq
MARKET: Health Tech to Station F, Paris
MARKET: Drones to Deep Tech
MARKETPLACE: media stories 2015-18
MARKET: Gazelles to Industrial Internet
COMPANIES: FinnCap to Florence
COMPANIES: Perkbox to Revolut
COMPANIES: Itsu to Cambridge Innovation Capital
MARKET: Bioelectronics to Chinese Investment
COMPANIES: Jellycat to Kymab
DZ elevator pitch
MARKET: Cash Burn to Workspace
New Year's resolution: visit Station F, Paris
MARKET: Spin-outs to Science Parks
MARKET: Startup Successes to Tech Nation
COMPANIES: Giraffe to Xupes
MARKET: Cyber Security to AI
Wendy Tan White to join BGF Ventures
Queen’s Awards for Enterprise winners 2016
COMPANIES: Alfa to Tokamak Energy
RT @drbexl: I support the @ICR_London manifesto to improve cancer #DrugAccess because I have Stage 4 incurable cancer and I want to know…
RT @lid_jar: I support the @ICR_London manifesto to improve cancer #DrugAccess because if my cancer ever comes back (TOUCH WOOD it never do…
RT @GillCraig: I support the @ICR_London manifesto to improve cancer #DrugAccess because everyone deserves the best and latest treatment ht…
Some more results from the patient survey that accompanies our new Cancer Drug Manifesto. These results are from so… https://t.co/suB0KXYQtM
Our donors and supporters play a vital role in helping us make the discoveries that defeat cancer. Find out more:… https://t.co/BKAtLoyGcs
RT @welliesnseaweed: I support the @ICR_London manifesto to improve cancer #DrugAccess because I want to know that if my cancer comes back…
Olaparib is currently only available on the NHS for #OvarianCancer but has been licensed for advanced breast cancer… https://t.co/XXjXPVpMBn
Emma was diagnosed with #BreastCancer in 2016. She is currently being treated with chemotherapy and will soon begin… https://t.co/0BvjyH3m3s
Our CEO, Professor Paul Workman, is speaking today (11:30 am) at the Westminster Health Forum policy conference. Hi… https://t.co/00QDBqVl8h